Clarion News

2020 ASCO GI Perspectives


The Clarion team was excited to attend the 2020 Gastrointestinal Cancers Symposium (ASCO GI) in order to stay abreast of the latest advances in cancer care so we can continue to effectively support our clients with the development of innovative strategies and solutions that improve patient lives. We are pleased to share the following insights from the conference:

Key Takeaways

  • “Everything beyond OS and QoL is a surrogate”: Measuring quality of life using patient-reported outcomes improves overall survival and is increasingly a subject of scrutiny and debate
  • Groundbreaking clinical trial designs such as ASCO’s real-world TAPUR study and PanCan’s adaptive and collaborative Precision Promise trial offer innovative signal-finding and potential paths to registration beyond classical randomized clinical trials
  • I-O combinations raise hopes: Studies combining anti-PD-(L)1 with TKIs like lenvatinib or other targeted agents continue to show the best efficacy to date across multiple GI cancers
  • I-O biomarker strategies are still evolving: JAVELIN Gastric 100, among other recent trial results, highlights the need for better predictive biomarkers and optimization of the ones we have


Click HERE to read the full perspectives for the 2020 Gastrointestinal Cancers Symposium

Is Clarion the right place to advance your career?

Find out more about joining Clarion’s team of innovation advisors.

A life sciences strategy and organizational consultancy that collaborates with its clients to envision, craft and enable growth through innovation and leadership.